Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery

Summary

This study analyzes the safety and efficacy of off-label Subconjunctival Injection of bevacizumab (Avastin) versus 0.02% mitomycin C (MMC) for preventing bleb failure following glaucoma filtration surgery.

Timeline

Start

2007-05

Primary completion

—

Completion

2007-12

Drugs

Indications